Modern tactics of treatment of relapsed/refractory multiple myelomaAuthor:Nemish I.L. Т. 13, № 3 (51)
Induction targeted therapy with tyrosine kinase inhibitors in the treatment of EGFR-positive non-small cell lung cancer. Clinical case and discussion of features of therapeutic «targeted» tumor pathomorphosisAuthors: Sukhoversha O.A. Tsyhankov K.V. Kuzhevskyi I.V. Koval S.S. Т. 13, № 2 (50)
Features of the surgical treatment of the breast cancer with grouped microcalcificationsAuthors: Smolanka I.I. (sen.) Movchan O.V. Lyashenko A.O. Loboda A.D.... Т. 13, № 2 (50)
Primary cutaneous t-cell lymphomas: classification, diagnosis, treatment (literature review)Authors: Kryachok I.A. Aleksyk O.M. Tytorenko I.B. Т. 13, № 2 (50)
Features of the impact of metabolic syndrome on the prostate cancer aggressivenessAuthor:Tymoshenko A.V. Т. 13, № 2 (50)
The most ponderable achievements scientific researches of the Nonprofit Organization National Cancer Institute in 2022Authors: Bankovska N.V. Zhurbenko A.V. Т. 13, № 2 (50)
A case of metachromic and synchronous secondary melanoma of the skinAuthors: Korovin S.I. Dyedkov S.A. Ostafiichuk V.V. Kolmykova A.V. Т. 13, № 2 (50)
Hereditary cancer genetic testing and breast cancer screening: a cost-effectiveness assessmentAuthors: Kostiuchenko Y. Iegorova E. Т. 13, № 2 (50)
Formation of radioiodine resistance in patients with differentiated thyroid cancer and possibilities of its prediction. Data from own research and literature were usedAuthors: Solodyannуkova O.I. Zelinskaya A.V. Danylenko V.V. Т. 13, № 2 (50)
The course features of HER2/neu-low breast cancerAuthors: Bondar M.V. Syvak L.A. Tarasenko T.Ye. Martynyuk O.M.... Т. 13, № 2 (50)
Clinical characteristics, treatment characteristics, and endpoints assessed in real-world clinical practice of talazoparib in patients with HER2-negative BRCA-associated breast cancerAuthor:Huyvanyuk O.A. Т. 13, № 2 (50)
The choice of adjuvant treatment of endometrial cancer III A-C stagesAuthors: Dyakiv I.B. Kryzhanivska A.E. Ryzhyk V.M. Sokolovska M.V.... Т. 13, № 2 (50)
Neck lymph node metastasis from unknown primary lesionAuthors: Halay O.O. Bilynskyi B.T. Bondarenko S.G. Duda O.R.... Т. 13, № 2 (50)
How to select the most valuable anticancer drugs for reimbursement? Experience of ESMO and WHOAuthor:Poliakova D. Т. 13, № 1 (49)
The role of T790M mutation in first- and second-line therapy of patients with EGFR-positive non-small cell lung cancerAuthors: Storozhenko S.A. Shparyk Ya.V. Т. 13, № 1 (49)
